Flunarizine

證據等級: L5

預測適應症: 1 個

Flunarizine: From Vertigo to Migraine Disorder

One-Sentence Summary

Flunarizine is a selective calcium channel blocker traditionally used for vertigo and vestibular disorders, widely established in Europe, Asia, and Latin America but not currently marketed in Canada. The TxGNN model predicts it may be effective for Migraine Disorder, with 19 clinical trials and 20 publications currently supporting this direction — evidence already at Level L1, anchored by multiple completed head-to-head RCTs and international clinical guidelines.

Quick Overview

Item	Content
Original Indication	Vertigo / Vestibular Disorders (traditional; no Canada DIN on file)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.12%
Evidence Level	L1
Canada Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Flunarizine is a selective calcium channel blocker acting primarily on voltage-dependent L- and T-type calcium channels. Its mechanism maps directly onto migraine pathophysiology at multiple levels: (1) it inhibits cortical spreading depression (CSD) — the core neurophysiological cascade underlying migraine aura and headache onset; (2) it suppresses abnormal neuronal firing within the trigeminal neurovascular system, dampening neurogenic inflammation; (3) it blocks calcium influx into cerebrovascular smooth muscle, preventing pathological vasospasm; and (4) its mild dopamine D2 receptor blockade activity may reduce central sensitization. Together, these complementary actions make flunarizine one of the most mechanistically well-founded options for migraine prevention.

The relationship between flunarizine’s traditional use in vertigo and its predicted efficacy in migraine is not coincidental. Vestibular migraine is a recognized migraine phenotype, and the shared calcium-mediated pathophysiology means that flunarizine addresses both conditions through the same receptor targets. The 2023 European Headache Federation meta-analysis (PMID 37723437) explicitly characterizes flunarizine as “a repurposed, first- or second-line treatment for migraine prophylaxis,” and it is listed on the WHO Essential Medicines List for this indication — further validating the TxGNN model’s prediction.

Compared to other first-line prophylactics, flunarizine occupies a distinct mechanistic niche: it complements β-blockers (propranolol) and antiepileptics (topiramate) and is particularly useful for patients who cannot tolerate those agents. Multiple completed head-to-head RCTs confirm its efficacy is comparable to propranolol, topiramate, and amitriptyline in both adult and pediatric populations. The Canadian Headache Society (2012) guideline already references flunarizine within its evidence framework, creating a strong foundation for a Canadian market authorization application.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03712917	NA	Completed	120	Three-arm RCT: direct head-to-head comparison of greater occipital nerve block (GONB), topiramate, and flunarizine for episodic migraine prevention; outcomes assessed by post-treatment VAS scores and attack frequency reduction
NCT02639598	Phase 4	Completed	62	Flunarizine 10 mg/day vs topiramate 50 mg/day for chronic migraine (CM) prophylaxis — one of the few head-to-head trials conducted specifically in the chronic migraine subpopulation
NCT06162819	NA	Unknown	84	RCT comparing flunarizine vs amitriptyline for migraine prophylaxis in a Pakistani tertiary care population; measured acute attack frequency and VAS pain scores across both sexes, ages 18–60
NCT07354126	NA	Recruiting	44	Pediatric RCT comparing flunarizine vs propranolol in children aged 8–15 using the validated PedMIDAS disability scale; addresses an evidence gap in the under-studied pediatric age group
NCT06499116	Phase 4	Not Yet Recruiting	460	PREMI pragmatic multicentre trial: four-arm comparison of amitriptyline, flunarizine, topiramate, and propranolol as first-line migraine prophylaxis in primary care (Spain); powered for real-world effectiveness comparison
NCT04064814	Phase 4	Completed	60	RCT evaluating alpha-lipoic acid as add-on nutraceutical to background flunarizine therapy in adolescent migraineurs; establishes flunarizine’s role as a standard reference treatment in adolescents
NCT00752466	Phase 1	Completed	75	PK/DDI open-label study examining pharmacokinetic interaction between flunarizine and topiramate during mono- and concomitant therapy; defines safety parameters for combination use
NCT00740259	Phase 4	Completed	70	Phase 4 RCT vs haloperidol testing flunarizine’s D2 receptor blockade hypothesis; provides long-term safety characterization including extrapyramidal symptoms, weight gain, and depression risk
NCT06753825	N/A	Active, Not Recruiting	60	Observational comparison of transcutaneous pulsed radiofrequency therapy vs calcium channel blockers (including flunarizine) for childhood migraine; explores long-term effectiveness
NCT04766762	NA	Unknown	96	RCT comparing acupuncture vs flunarizine hydrochloride as active comparator for migraine without aura; validates flunarizine as the standard-of-care reference arm in this setting

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37723437	2023	Systematic Review + Meta-Analysis	J Headache Pain (EHF)	EHF critical re-appraisal confirming flunarizine as an evidence-based, repurposed first/second-line migraine prophylactic; formally rates strength of evidence for regulatory reimbursement decisions
40553594	2025	Systematic Review + Meta-Analysis	J Assoc Physicians India	Comparative meta-analysis of amitriptyline vs propranolol and flunarizine for migraine prophylaxis; flunarizine demonstrates comparable efficacy with a distinct side-effect profile
39388181	2024	Network Meta-Analysis	JAMA Network Open	Network meta-analysis across pharmacological interventions for pediatric migraine prophylaxis; positions flunarizine within the comparative efficacy and safety landscape for children and adolescents
39365169	2024	Systematic Review + Economic Model	Health Technol Assess	Systematic review comparing clinical effectiveness and cost-effectiveness of chronic migraine preventive drugs vs newer CGRP monoclonal antibodies; informs payer reimbursement frameworks
22683887	2012	Clinical Practice Guideline (CHS)	Can J Neurol Sci	Canadian Headache Society guideline for migraine prophylaxis in episodic migraine (≤14 headache days/month); directly relevant to the Canadian regulatory and prescribing context
31413170	2019	Clinical Practice Guideline (AAN)	Neurology	AAN/AHS updated evidence-based guideline for pharmacologic prevention of pediatric migraine, with specific evidence grading for flunarizine use in children
30428122	2019	RCT	Acta Neurol Scand	RCT demonstrating that flunarizine combined with transcutaneous supraorbital neurostimulation (tSNS) significantly improves migraine prophylaxis outcomes compared to either modality alone
9443168	1997	Post-Marketing Study	Pharm World Sci	Large prospective post-marketing study (n=686 migraine patients) comparing flunarizine vs propranolol; documents risk/benefit ratio including incidence of depression and extrapyramidal syndrome in real-world use
3878734	1985	Clinical Study	Cephalalgia	Foundational study (n=75 migraine patients) establishing flunarizine 10 mg/day efficacy: 78.5% of treated patients showed favourable headache response; also characterized vestibular function effects
35791513	2022	Clinical Trial	Brain Behav	Clinical evaluation of flunarizine combined with duloxetine for chronic migraine comorbid with depression and anxiety disorder; characterizes a high-prevalence comorbidity scenario in clinical practice

Canada Market Information

Flunarizine has no active Drug Identification Numbers (DINs) in Canada and is not currently marketed. No licensed products are on file with Health Canada.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN model’s prediction for flunarizine in migraine disorder is supported by the strongest available level of clinical evidence (L1), including multiple completed Phase 4 head-to-head RCTs, a 2023 European Headache Federation meta-analysis, two international clinical practice guidelines (Canadian Headache Society 2012; AAN/AHS 2019), and WHO Essential Medicines List inclusion — making this one of the most evidence-rich drug repurposing candidates in this pipeline.

To proceed, the following is needed:

Health Canada regulatory pathway assessment: Determine whether a New Drug Submission (NDS) or a hybrid pathway applies given flunarizine’s long global post-marketing history
Safety dossier: Retrieve and formally review the product monograph/package insert to characterize extrapyramidal symptoms, depression risk, and drug-drug interaction profile per Health Canada standards
Canadian market positioning: Reconcile with the 2012 Canadian Headache Society guideline and assess competitive positioning vs currently approved prophylactics (propranolol, topiramate, amitriptyline, CGRP monoclonal antibodies)
Formulation confirmation: Flunarizine is typically available as 5 mg and 10 mg capsules — confirm the target dosage form, strength, and route for the Canadian filing
Pediatric data package: Given the evidence gap in pediatric populations specifically noted in the AAN guideline, determine whether a pediatric investigation plan is required
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.